MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/hep.22517

Медицинская библиотека · Hepatology (Baltimore, Md.) · 2008

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.

Mayo Marlyn J, Parkes Julie, Adams-Huet Beverley, Combes Burton, Mills A S, Markin Rodney S, Rubin Raphael, Wheeler Donald, Contos Melissa, West A B, Saldana Sandra, Getachew Yonas, Butsch Robert, Luketic Velimir, Peters Marion, Di Bisceglie Adrian, Bass Nathan, Lake John, Boyer Thomas, Martinez Enrique, Boyer James, Garcia-Tsao Guadalupe, Barnes David, Rosenberg William M

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

UNLABELLED: Primary biliary cirrhosis (PBC) is sometimes diagnosed based on a positive antimitochondrial antibody in the appropriate clinical setting without a liver biopsy. Although a liver biopsy can assess the extent of liver fibrosis and provide prognostic information, serum fibrosis markers avoid biopsy complications and sampling error and provide results as a continuous variable, which may be more precise than categorical histological stages. The current study was undertaken to evaluate serum fibrosis markers as predictors of clinical progression in a large cohort of PBC patients. Serial liver biopsy specimens and serum samples were collected every 2 years in 161 PBC subjects for a median of 7.3 years. Clinical progression was defined as development of one or more of the following events: varices, variceal bleed, ascites, encephalopathy, liver transplantation, or liver-related death. Serum hyaluronic acid, tissue inhibitor of metalloproteinase 1, and procollagen III aminopeptide were measured and entered into the previously validated enhanced liver fibrosis (ELF) algorithm. The ability of ELF, histological fibrosis, bilirubin, Model for End-Stage Liver Disease (MELD), and Mayo Risk Score to differentiate between individuals who would experience a clinical event from those who would not was evaluated at different time points. Event-free survival was significantly lower in those with high baseline ELF. Each 1-point increase in ELF was associated with a threefold increase in future complications. The prognostic performance of all tests was similar when performed close to the time of the first event. However, at earlier times in the disease process (4 and 6 years before the first event), the prognostic performance of ELF was significantly better than MELD or Mayo R score.

CONCLUSION

The ELF algorithm is a highly accurate noninvasive measure of PBC disease severity that provides useful long-term prognostic information.

Для цитирования: Mayo Marlyn J, Parkes Julie, Adams-Huet Beverley, Combes Burton, Mills A S, Markin Rodney S, Rubin Raphael, Wheeler Donald, Contos Melissa, West A B, Saldana Sandra, Getachew Yonas, Butsch Robert, Luketic Velimir, Peters Marion, Di Bisceglie Adrian, Bass Nathan, Lake John, Boyer Thomas, Martinez Enrique, Boyer James, Garcia-Tsao Guadalupe, Barnes David, Rosenberg William M. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.. Hepatology (Baltimore, Md.). 2008. DOI: 10.1002/hep.22517.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.